Dorian Bevec

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Dorian Bevec is a German molecular biologist, Chief Scientific Officer and co-founder at Mondobiotech.[1] He was born on May 21, 1957, in Zagreb, FPR Yugoslavia.


  • 1980 B.Sc. in general biology, Justus-Liebig-University,[2] Giessen, Germany
  • 1983 M.Sc. in biology, Justus-Liebig-University, Giessen, Germany
  • 1984 Visiting Scientist at the Basel Institute for Immunology, Lab. Michael Steinmetz, Basel, Switzerland
  • 1983–1985 Scientist at the Institute of Virology, Justus-Liebig-University, Giessen, Germany
  • 1985–1988 Scientist at the Laboratory for Molecular Biology of the Ludwig-Maximilians-University, in Munich, Germany
  • 1988–1989 Post-doctoral Research Fellow at Sandoz Research Institute, Vienna, Austria
  • 1989 Ph.D. in biology, Ludwig Maximilians-University, Munich, Germany

Scientific career[edit]

From 1989–1990 he was laboratory head at the Department of Immunopharmacology at Sandoz Research Institute, Vienna, Austria, and, after a year as Visiting scientist at the Memorial Sloan-Kettering Cancer Center, Laboratory Head, Department of Anti-Retroviral Therapy at Sandoz. In 1996, he became Head of the Molecular Biology Group there. In 1997 he received the Dr. habil. in human virology from the University of Vienna. He then joined Novartis Research Institute as Programme Team Head, Department of Immunology, and, in 1999, became Group Leader and Vice President, Research & Head of Platform Technologies at Axxima Pharmaceuticals AG, Martinsried, Germany; in 2001 he co-founded Mondobiotech Group, Stans, Switzerland, where he took the position of Chief Scientific Officer.

Selected publications[edit]

  • W. Schmidt, U. Henseling, D. Bevec, A.D.R. Alonzo and H. Festenstein. Control of synthesis and expression of H-2 heavy chain and beta-2 microglobulin in AKR leukemias. Immunogenetics, 1985, 22, 483-494.
  • W. Schmidt, G. Noll, D. Bevec and U. Henseling. Aberrant MHC antigens in a sarcoma virus-induced mouse tumour. J. Immunogenetics, 1986, 13, 123-132.
  • P.J. Robinson, D. Bevec, A.L. Mellor and E.H. Weiss. Sequence of the mouse Q4 class I gene and characterization of the gene product. Immunogenetics, 1988, 27, 79-86.
  • E.H. Weiss, D. Bevec, G. Messer, S. Schwemmle, C. Grosshaus, M. Steinmetz and W. Schmidt. Organization of the AKR Qa region: Structure of a divergent class I sequence, Q5k. J. Immunogenetics, 1989, 16, 283-290.
  • H.E. Feucht, J. Zwirner, D. Bevec, M. Lang, E. Felber, G. Riethmüller and E.H. Weiss. Biosynthesis of complement C4 messenger RNA in normal human kidney. Nephron, 1989, 53, 338-342.
  • S. Schwemmle, D. Bevec, G. Brem, M.B. Urban, P.A. Baeuerle and E.H. Weiss. Developmental and tissue-specific expression of the Q5k gene. Immunogenetics, 1991, 34, 28-38.
  • P. Valent, D. Bevec, D. Maurer, J. Besemer, F. Di Padova, J.H. Butterfield, W. Speiser, O. Majdic, K. Lechner and P. Bettelheim. Interleukin 4 promotes expression of mast cell ICAM-1 antigen. Proc. Natl. Acad. Sci. USA, 1991, 88, 3339-3342.
  • S. Kapiotis, J. Besemer, D. Bevec, P. Valent, P. Bettelheim, K. Lechner and W. Speiser. Interleukin-4 counteracts pyrogen-induced downregulation of thrombomodulin in cultured human vascular endothelial cells. Blood, 1991, 78, 410-415.
  • C. Sillaber, H. Strobl, D. Bevec, L.K. Ashman, J.H. Butterfield, K. Lechner, D. Maurer, P. Bettelheim and P. Valent. IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J. Immunol.,1991, 12, 4224-4228.
  • D. Seebach, S.Y. Ko, H. Kessler, M. Köck, M. Reggelin, P. Schmieder, M.D. Walkinshaw, J.J. Bölsterli and D. Bevec. Thiocyclosporins: Preparation, solution and crystal structure, and immunosuppressive activity. Helv. Chim. Acta 1991, 74, 1953-1990.
  • C.S.N. Chujor, B. Kuhn, B. Schwerer, H. Bernheimer, W.R. Levis and D. Bevec. Specific inhibition of mRNA accumulation for lymphokines in human T cell line Jurkat by mycobacterial lipoarabinomannan antigen. Clin. Exp. Immunol., 1992, 87, 398-403.
  • K. Zimmermann, M. Dobrovnik, C. Ballaun, D. Bevec, J. Hauber and E. Böhnlein. Trans-activation of the HIV-1 LTR by the HIV-1 Tat and HTLV-I Tax proteins is mediated by different cis-acting sequences. Virology, 1991, 182, 874-878.
  • R. Schreck, D. Bevec, P. Dukor, P.A. Baeuerle, L. Chedid and G.M. Bahr. Selection of a muramyl peptide based on its lack of activation of nuclear factor - kappa B as a potential adjuvant for AIDS vaccines. Clin. Exp. Immunol., 1992, 90, 188-193.
  • D. Bevec, M. Dobrovnik, J. Hauber and E. Böhnlein. Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc. Natl. Acad. Sci. USA, 1992, 89, 9870-9874.
  • D. Bevec, J. Hauber and E. Böhnlein. Intracellular immunization against HIV-1: Rev as a potential target for gene intervention. Int. Antiviral News, 1993, 1, 86-87.
  • C. Sillaber, D. Bevec, J. H. Butterfield, R. Valenta, C. Heppner, O. Scheiner, D. Kraft, K. Lechner, P. Bettelheim and P. Valent. Tumor necrosis factor-alfa and Interleukin-1 beta mRNA expression in HMC-1 cells: Differential regulation of gene product expression by recombinant IL-4. Exp. Hematology, 1993, 21, 1271-1275.
  • M. Ruhl, M. Himmelspach, G.M. Bahr, F. Hammerschmid, H. Jaksche, B. Wolff, H. Aschauer, G.K. Farrington, H. Probst, D. Bevec and J. Hauber. Eukaryotic initiation factor 5A is a cellular target of the HIV-1 Rev activation domain mediating trans-activation. J. Cell Biol., 1993, 123, 1309-1320.
  • D. Bevec, B. Volc-Platzer, K. Zimmermann, M. Dobrovnik, J. Hauber, G. Veres and E. Böhnlein. Constitutive expression of chimeric neo-rev response element transcripts suppresses HIV-1 replication in human CD4+ T-lymphocytes. Human Gene Therapy, 1994, 5, 193-201.
  • S. Kapiotis, P. Quehenberger, G. Sengoelge, C. Pärtan, R. Eher, H. Strobl, D. Bevec, D. Zapolska, I. Schwarzinger and W. Speiser. Modulation of pyrogen-induced upregulation of endothelial cells adhesion molecules (CAMs) by Interleukin-4: Transcriptional regulation and CAM-shedding. Circ. Shock, 1994, 43, 18-25.
  • K. Koettnitz, B. Kappel, T. Baumruker, J. Hauber and D. Bevec. Genomic structure of the gene coding for human eukaryotic initiation factor 5A. Gene, 1994, 144, 249-252.
  • U. Junker, K. Rittner, M. Homann, D. Bevec, E. Böhnlein and G. Sczakiel. Reduction in replication of the human immunodeficiency virus type 1 in human T cell lines by polymerase III - driven transcription of chimeric tRNA-antisense RNA genes. Antisense Res. and Dev., 1994, 4, 165-172.
  • G. M. Bahr, E. Darcissac, D. Bevec, P. Dukor and L. Chedid. Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on Murabutide. Int. J. of Immunopharmacology, 1995, 17,117-131.
  • A. Cerwenka, D. Bevec, O. Majdic, W. Knapp and W. Holter. Transforming growth factor b is a potent inducer of human effector T-cells. J. Immunol., 1994, 153, 4367-4377.
  • D. Bevec, H. Klier, W. Holter, E. Tschachler, P, Valent, F. Lottspeich, T. Baumruker and J. Hauber. Induced gene expression of the hypusine-containing protein eukaryotic initiation factor 5A in activated human T-lymphocytes. Proc. Natl. Acad. Sci. USA, 1994, 91, 10829-10833.
  • K. Koettnitz, T. Wöhl, B. Kappel, F. Lottspeich, J. Hauber and D. Bevec. Identification of a new member of the human initiation factor eIF-5A gene family. Gene, 1995, 159, 283-284.
  • A. Steinkasserer, T. Jones, D. Sheer, K. Koettnitz, J. Hauber and D. Bevec. The eukaryotic cofactor for the human immunodeficiency virus type 1 (HIV-1) Rev protein, eIF-5A, maps to chromosome 17p12-13. Three eIF-5A pseudogenes map to 10q23.3, 17q25 and 19q13.2. Genomics, 1995, 25, 749-752.
  • D. Bevec, B. Kappel, H. Jaksche, R. Csonga, J. Hauber, H. Klier and A. Steinkasserer. Molecular characterization of a cDNA encoding functional human deoxyhypusine synthase and chromosomal mapping of the corresponding gene locus. FEBS Letters, 1996, 378, 195-198.
  • M. Baghestanian, H. Agis, D. Bevec, H. C. Bankl, R. Hofbauer, H. G. Kress, J. H. Butterfield, M. R. Müller, L. K. Ashman, W. Füreder, M. Willheim, K. Lechner and P. Valent. Stem cell factor-induced downregulation of c-kit in human lung mast cells and HMC-1 mast cells. Exp. Hematology, 1996, 24, 1377-1386.
  • D. Bevec, H. Jaksche, M. Oft, T. Wöhl, M. Himmelspach, A. Pacher, M. Schebesta, K. Koettnitz, M. Dobrovnik, R. Csonga, F. Lottspeich and J. Hauber. Inhibition of HIV-1 replication in human CD4+ T lymphocytes by expression of mutants of the Rev cofactor eIF-5A. Science, 1996, 271, 1858-1860.
  • S. Kapiotis, G. Sengoelge, W. R. Sperr, M. Baghestanian, P. Quehenberger, D. Bevec, S. R. Li, E. J. Menzel, A. Mühl, I. Virgolini, P. Valent and W. Speiser. Ibuprofen inhibits pyrogen-dependent expression of VCAM-1 and ICAM-1 on human endothelial cells. Life Science, 1996, 58, 2167-2181.
  • T. Jones, D. Sheer, A. Kapetanopoulos, J. Hauber, D. Bevec and A. Steinkasserer. The gene coding for Human Deoxyhypusine Synthase (DHPS) maps to chromosome 19p13.11-p13.12. Genomics, 1996, 35, 635-637.
  • U. Junker, D. Bevec, C. Barske, C. Kalfoglou, S. Escaich, M. Dobrovnik, J. Hauber and E. Böhnlein. Intracellular expression of cellular eIF-5A mutants inhibits HIV-1 replication in human T-cells: A feasibility study. Human Gene Therapy, 1996, 7, 1861-1869.
  • U. Junker, D. Bevec, J. Hauber and E. Böhnlein. Mutant host cellular factors required for HIV-1 replication represent new targets for HIV-1 gene therapy. Int. Antiviral News, 1996, 4, 191-193.
  • E. Mlynar, D. Bevec, A. Billich, B. Rosenwirth and A. Steinkasserer. The nonimmunosuppressive Cyclosporin A analog SDZ NIM 811 inhibits viral Cyclophilin A incorporation and viral replication in HIV-1 infected primary and growth-arrested T-cells. J. of General Virology, 1997, 78, 825-835.
  • T. Jones, D. Sheer, D. Bevec, B. Kappel, J. Hauber and A. Steinkasserer. The human HIV-1 Rev binding-protein hRIP/Rab maps to chromosome 2q36. Genomics, 1997, 40, 198-199.
  • C. Sillaber, M. Baghestanian, R. Hofbauer, I. Virgolini, H.C. Bankl, W. Füreder, H. Agis, M. Wilhelm, M. Leimer, O. Scheiner, B.R. Binder, H. Kiener, D. Bevec, G. Fritsch, O. Majdic, H.G. Kress, H. Gadner, K. Lechner and P. Valent. Molecular and functional characterization of the urokinase receptor on human mast cells. J. Biol. Chem., 1997, 272, 7824-7832.
  • D. Bevec and J. Hauber. Eukaryotic Initiation Factor 5A activity and HIV-1. Rev function. Biol. Signals,1997, 6, 124-133.
  • M. Baghestanian, R. Hofbauer, H.P. Kiener, H.C. Bankl, F. Wimazal, M. Wilhelm, O. Scheiner, W. Füreder, M.R. Müller, D. Bevec, K. Lechner and P. Valent. The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein-1 in human lung mast cells. Blood, 1997, 90, 4438-4449.
  • O. Schatz, M. Oft, C. Dascher, M. Schebesta, O. Rosorius, H. Jaksche, M. Dobrovnik, D. Bevec and J. Hauber. Interaction of the HIV-1 Rev cofactor eukaryotic initiation factor 5A with ribosomal protein L5. Proc. Natl. Acad. Sci. USA,1998, 95, 1607-1612.
  • S. Thomas, M. Oft, H. Jaksche, G. Casari, P. Heger, M. Dobrovnik, D. Bevec and J. Hauber. Functional analysis of the Human Immunodeficiency Type 1 Rev protein oligomerization interface. J. Virol., 1998, 72, 2935-2944.
  • C. Sillaber, M. Baghestanian, D. Bevec, M. Willhelm, H. Agis, S. Kapiotis, W. Füreder, H.C. Bankl, H Kiener, W. Speiser, B.R. Binder, K Lechner and P. Valent. The mast cell as site of tissue type plasminogen activator expression and fibrinolysis. J. Immunol., 1999, 162, 1032-1041.
  • C. Elfgang, O. Rosorius, L. Hofer, H. Jaksche, J. Hauber and D. Bevec. Evidence for specific nucleocytoplasmic pathways used by leucine-rich nuclear export signals. Proc. Natl. Acad. Sci. USA., 1999, 96, 6229-6234.
  • O. Rosorius, B. Fries, R. Stauber, N. Hirschmann, D. Bevec and J. Hauber. Human ribosomal protein L5 contains defined nuclear localization and export signals. J. Biol. Chem., 2000, 275, 12061-12068.
  • M. Kruse, O. Rosorius, F. Krätzer, D. Bevec, C. Kuhnt, A. Steinkasserer, G. Schuler and J. Hauber: Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA. J. Exp. Med., 2000, 191, 1-10.
  • J. Schultz, T. Jones, P. Bork, D. Sheer, S. Blencke, S. Steyrer, U. Wellbrock, D. Bevec, A. Ullrich and C. Wallasch. Molecular characterization of a cDNA encoding functional human Clk4 kinase and localization to chromosome 4q35. Genomics, 2001, 71, 368-370.
  • G.H. Schernthaner, J.H. Jordan, M. Ghannadan, H. Agis, D. Bevec, R. Nunez, L. Escribano, O. Majdic, M. Willheim, C. Worda, D. Printz, G. Fritsch, K. Lechner, and P. Valent. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood 2001, 98, 3784-3792.
  • Wallasch, J.E. Crabtree, D. Bevec, P.A. Robinson, H. Wagner, and A. Ullrich. Helicobacter pylori-stimulated EGF receptor transactivation requires metalloprotease cleavage of HB-EGF. Biochem Biophys Res Commun 2002, 295, 695-701.
  • Baghestanian, J.H. Jordan, H.P. Kiener, D. Bevec, H. Agis, G. Fritsch, M.R. Muller, H.C. Bankl, G. H. Schernthaner, K. Lechner, and P. Valent. Activation of human mast cells through stem cell factor receptor (KIT) is associated with expression of bcl-2. Int Arch Allergy Immunol. 2002, 129, 228-236.
  • M.N. Sommer, D. Bevec, B. Klebl, B. Flicke, K. Holscher, T. Freudenreich, I. Hauber, J. Hauber, and H. Mett. Screening assay for the identification of deoxyhypusine synthase inhibitors. J Biomol Screen. 2004, 9, 434-438.
  • I. Hauber, D. Bevec, J. Heukeshoven, F. Krätzer, F. Horn, A. Choidas, T. Harrer, and J. Hauber. Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy. J. Clin. Invest. 2005, 115, 76-85.
  • B. Schäfer, I. Hauber, A. Bunk, J Heukeshoven, A Düsedau, D. Bevec, and J Hauber. Inhibition of multidrug-resistant HIV-1 by interference with cellular S-adenosylmethionine decarboxylase activity. J. Infect. Dis. 2006, 194, 740-750.
  • Specht S, Sarite SR, Hauber I, Hauber J, Görbig UF, Meier C, Bevec D, Hoerauf A, and Kaiser A. The guanylhydrazone CNI-1493: an inhibitor with dual activity against malaria-inhibition of host cell pro-inflammatory cytokine release and parasitic deoxyhypusine synthase. Parasitol Res. 2008 Feb 7; [Epub ahead of print]


External links[edit]